BioWorld

Sep. 29, 2003

View Archived Issues

Novogen Cancer Subsidiary Files IPO, Seeks Up To $13M

Read More

Chromosome 15's 4 Mutant Genes Focus Hotspots For Derangements In Michigan, Penn Research Centers

Read More

Hollis-Eden Raises $62.5M; This Time In Public Offering

Read More

Angiotech Garners $218.8M With Follow-On Public Stock Offering

Read More

Appointments And Advancements

Read More

Other News To Note

Read More

After Phase II Miss, HGS Stops Repifermin Venous Ulcers Work

Human Genome Sciences Inc. said it would terminate development of repifermin in chronic venous ulcers following a disappointing Phase II trial. (BioWorld Today) Read More